NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 223)
Posted On: 04/01/2020 3:14:47 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Full-Year 2019
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today released financial results for its full year ended December 31, 2019, as well as select corporate highlights. Among the highlights, the company reported its securing of a $15.0 million equity line with Oasis Capital, LLC, as well as its new subsidiary, Helomics, reaching milestone sequencing tumor cases in partnership with UPMC Magee. “2019 was not without its challenges for the entire healthcare technology industry, yet we continued to execute on our business model, making a synergistic acquisition and shoring up our balance sheet via a new $15.0 million equity line from Oasis Capital,” Predictive Oncology CFO Bob Myers said in the news release. “Our STREAMWAY line has maintained strong disposable product sales and we continue to sell the STREAMWAY System.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today released financial results for its full year ended December 31, 2019, as well as select corporate highlights. Among the highlights, the company reported its securing of a $15.0 million equity line with Oasis Capital, LLC, as well as its new subsidiary, Helomics, reaching milestone sequencing tumor cases in partnership with UPMC Magee. “2019 was not without its challenges for the entire healthcare technology industry, yet we continued to execute on our business model, making a synergistic acquisition and shoring up our balance sheet via a new $15.0 million equity line from Oasis Capital,” Predictive Oncology CFO Bob Myers said in the news release. “Our STREAMWAY line has maintained strong disposable product sales and we continue to sell the STREAMWAY System.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)